SUPPORTING INFORMATION
Supplemental Figure S1. The HRAS and BRAF detected mutations in the RMS
patient.
Supplemental Figure S2. IGV of the detected mutations.
Supplemental Figure S3. Percent frequency of co-occurrence of HRAS
mutations with BRAF classes I, II and III in cBioportal.
Supplemental Figure S4. Diagram of Class I, II and III BRAF mutations
and the possible CLASS III inhibitors.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.
ACKNOWLEDGMENTS
Funding This work was supported by grants from Qatar National Research
Fund (QNRF grant
PPM 05-0316-210001)
AUTHORS CONTRIBUTION
S.S. Processed the WES data, collected the public data, performed the
bioinformatic analysis and drafted the manuscript. W.H. Supervised the
WES bioinformatic processing pipelines. C.R. extracted the DNA. A.M.
Collected the clinical data. C.R. W.H., D.B., A.M., and W.M.
participated in the interpretation of the results.